Evaxion Biotech (EVAX) to implement ADS ratio change
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Evaxion announces plan to implement ADS ratio change
December 30, 2024 8:00 AM ESTCOPENHAGEN, Denmark, December 30, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (Evaxion), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, today announced that it plans to change the ratio of its American Depositary Shares (ADSs) to its ordinary shares, DKK 1 nominal value (the ADS ratio), from the current one (1) ADS representing ten (10) ordinary share to a new ADS ratio of one (1) ADS representing fifty (50) ordinary shares (the ADS ratio change). The ADS ratio change is expected to become effective on or about January 13, 2025, U.S. Eastern Time (the effective date).
... More


